HISTORI authors answer comment on semaglutide trial in schizophrenia

The wire

1. 01Diabetes Care published the investigators' response to a letter about HISTORI, which assessed semaglutide's effects on insulin sensitivity and beta-cell function.
2. 02Patients on second-generation antipsychotics are a high-risk metabolic population where incretin use is increasingly discussed by prescribers.
3. 03This is correspondence rather than new data; the underlying 30-week trial results remain the substantive source.

From the source

Response to Comment on Ganeshalingam et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly

Diabetes care · 2026 Oct 20 · Ganeshalingam AA, Uhrenholt N, Bilenberg N et al.